Literature DB >> 2732334

Improvement of speech intelligibility by a secondary operation to mobilize the tongue after glossectomy.

K Michi1, S Imai, Y Yamashita, N Suzuki.   

Abstract

To prove the hypothesis that speech after glossectomy would be improved more by increasing the mobility of the remaining tongue rather than by increasing its volume, the speech intelligibility of 4 glossectomy patients was investigated before and after a secondary operation in which a split skin graft was used to mobilize the residual tongue. In each case, the postoperative speech intelligibility scores were higher than preoperative ones (case 1:83.6 to 97.2%, case 2: 76.6 to 82.5%, case 3: 51.5 to 58.5%, case 4: 30.2 to 49.3%). Sounds produced with the rear portion of the tongue were improved in 3 cases, and plosive and affricative sounds were remarkably improved in all cases. These results were considered to be due to the increased mobility, especially the mid and rear portions of the tongue.

Entities:  

Mesh:

Year:  1989        PMID: 2732334     DOI: 10.1016/s1010-5182(89)80015-0

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  3 in total

1.  Development of a new lingual range-of-motion assessment scale: normative data in surgically treated oral cancer patients.

Authors:  C L Lazarus; H Husaini; A S Jacobson; J K Mojica; D Buchbinder; D Okay; M L Urken
Journal:  Dysphagia       Date:  2014-05-09       Impact factor: 3.438

2.  Variation in compensatory strategies as a function of target constriction degree in post-glossectomy speech.

Authors:  Christina Hagedorn; Yijing Lu; Asterios Toutios; Uttam Sinha; Louis Goldstein; Shrikanth Narayanan
Journal:  JASA Express Lett       Date:  2022-04-22

3.  Complexity of vocal tract shaping in glossectomy patients and typical speakers: A principal component analysis.

Authors:  Christina Hagedorn; Jangwon Kim; Uttam Sinha; Louis Goldstein; Shrikanth S Narayanan
Journal:  J Acoust Soc Am       Date:  2021-06       Impact factor: 2.482

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.